Healthcare Supply Chain Management

The Future of Pharma Supply Chain Resilience Isn’t Incremental — It’s Radical Today’s supply chain challenges pushed me to revisit this critical topic and distill where true pharma resilience is heading. Diversifying suppliers and building safety stock? That’s table stakes. That’s 2020 thinking. The companies pulling ahead in 2026 aren’t just managing risk , they’re redesigning the system. Here’s what genuinely innovative resilience looks like today: - Agentic AI That Makes Decisions, Not Just Recommendations AI is moving from pilots to autonomous systems that take operational decisions independently. We’re shifting from dashboards that flag problems to systems that reroute supply chains before disruptions are even visible. The real question is no longer “should we use AI?” but “do we trust it enough to act without us?” - Digital Twins for the Entire Supply Network Leading pharma players now run live digital replicas of their full supply chains, stress-testing scenarios such as port closures or supplier failures in real time. This isn’t IT infrastructure — it’s a strategic war room. - Smart Factories as Resilience Infrastructure Smart factories integrating IoT, robotics, and cloud platforms are enabling agility across portfolios from generics to complex biosimilars. Flexibility has become the new efficiency. - True Multi-Regional Architecture The industry is moving away from cost-driven just-in-time models/countries toward genuine diversification. - Blockchain-Enabled Transparency Blockchain-based traceability is eliminating blind spots, making counterfeiting and quality fraud far harder to hide through immutable, end-to-end visibility. - Continuous Manufacturing Over Batch Batch manufacturing remains fragile. Continuous manufacturing reduces risk, accelerates response to demand shifts, and is supported by regulators — yet adoption is still lagging. - Real-Time Demand Sensing (Not Forecasting) Forecasting is often an educated guess. Real-time demand sensing uses live signals to shrink the gap between demand detection and response from months to days. The bottom line: The pharma companies that will win the next decade won’t be those with the biggest safety stock, but those with intelligent, networked, and self-correcting supply chains. Resilience is no longer a cost center — it’s a competitive weapon.

Over the past weeks, headlines have again reminded us how fragile the global context remains. Escalation in the Middle East, the continued war in Ukraine, disrupted trade routes and rising transport uncertainty are no longer distant geopolitical issues, they are part of the operating reality healthcare systems face today. In this environment, healthcare systems are learning a hard truth: reliability matters as much as efficiency, and often more than price. When uncertainty rises, the question shifts. It’s no longer just “can you supply?” It becomes “will you still be there when it gets hard?”. Clinicians and healthcare leaders have lived the consequences of fragile supply chains over recent years. Shortages, substitutions and delays do not stay on spreadsheets. They surface in operating rooms, wards and already overstretched teams at precisely the moments when resilience matters most. This is why supply chain resilience deserves a more nuanced, healthcare‑centered conversation. What has become clearer to me is that supply chain resilience is not about where a company is headquartered or the flag on its logo. An American MedTech company may manufacture predominantly in Europe. A European one may rely heavily on Asian components. What truly matters is how deliberately the supply chain has been designed, governed and prepared for disruption. As a result, reliability has become a core element of differentiation not as an abstract concept, but as a practical enabler of healthcare continuity. The organizations that have earned trust during recent disruptions didn’t do so by chance. They made deliberate, and often uncomfortable, choices such as: - Diversifying manufacturing and critical suppliers - Building flexibility into logistics and transport - Holding inventory where failure has clinical consequences, not just where spreadsheets optimize turns - Connecting procurement, operations, regulatory strategy, quality of care and ESG into a single system view This shift also has implications for procurement and tender design. The most robust decisions increasingly ask questions like: - How resilient and diversified is the manufacturing and supply footprint? - What options exist if a site, supplier or transport route is disrupted? - Where is inventory held relative to areas of highest clinical risk? - How are regulatory, logistics and operational decisions coordinated under stress? - What contingencies are in place before they are needed? Embedding these questions early helps healthcare systems move beyond unit price as the default and select partners capable of sustaining care delivery when conditions deteriorate. In MedTech, trust travels quietly through the supply chain. Reliability isn’t always visible until it is missing. I explore this further in the article below and would genuinely love to hear your perspective #SupplyChain #Healthcare #MedTech #Resilience #Procurement #geopoliticalconflicts #healthcarecontinuity

𝙅𝙪𝙨𝙩-𝙞𝙣-𝙏𝙞𝙢𝙚 𝙫𝙨. 𝙅𝙪𝙨𝙩-𝙞𝙣-𝘾𝙖𝙨𝙚: The Critical Balance in Procurement! The pandemic taught healthcare procurement professionals a lesson we won't soon forget: efficiency alone cannot be our North Star. For years, our industry embraced 𝙅𝙪𝙨𝙩-𝙞𝙣-𝙏𝙞𝙢𝙚 (JIT) procurement which focused on: ✔️𝙢𝙞𝙣𝙞𝙢𝙞𝙯𝙞𝙣𝙜 𝙞𝙣𝙫𝙚𝙣𝙩𝙤𝙧𝙮, ✔️𝙧𝙚𝙙𝙪𝙘𝙞𝙣𝙜 𝙘𝙤𝙨𝙩𝙨, 𝙖𝙣𝙙 ✔️𝙨𝙩𝙧𝙚𝙖𝙢𝙡𝙞𝙣𝙞𝙣𝙜 𝙤𝙥𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨. It worked beautifully... until it didn't. Today, I'm seeing a strategic shift toward a hybrid model that incorporates 𝙅𝙪𝙨𝙩-𝙞𝙣-𝘾𝙖𝙨𝙚 (JIC) principles. This isn't about stockpiling without strategy, but rather about: ✔️ 𝘽𝙪𝙞𝙡𝙙𝙞𝙣𝙜 𝙧𝙚𝙙𝙪𝙣𝙙𝙖𝙣𝙘𝙮 𝙞𝙣𝙩𝙤 𝙘𝙧𝙞𝙩𝙞𝙘𝙖𝙡 𝙨𝙪𝙥𝙥𝙡𝙮 𝙘𝙖𝙩𝙚𝙜𝙤𝙧𝙞𝙚𝙨 ✔️ 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙞𝙣𝙜 𝙧𝙚𝙜𝙞𝙤𝙣𝙖𝙡 𝙨𝙪𝙥𝙥𝙡𝙞𝙚𝙧 𝙣𝙚𝙩𝙬𝙤𝙧𝙠𝙨 𝙩𝙤 𝙧𝙚𝙙𝙪𝙘𝙚 𝙜𝙚𝙤𝙜𝙧𝙖𝙥𝙝𝙞𝙘 𝙫𝙪𝙡𝙣𝙚𝙧𝙖𝙗𝙞𝙡𝙞𝙩𝙞𝙚𝙨 ✔️ 𝙄𝙣𝙫𝙚𝙨𝙩𝙞𝙣𝙜 𝙞𝙣 𝙥𝙧𝙚𝙙𝙞𝙘𝙩𝙞𝙫𝙚 𝙖𝙣𝙖𝙡𝙮𝙩𝙞𝙘𝙨 𝙩𝙤 𝙖𝙣𝙩𝙞𝙘𝙞𝙥𝙖𝙩𝙚 𝙙𝙞𝙨𝙧𝙪𝙥𝙩𝙞𝙤𝙣𝙨 ✔️ 𝘾𝙧𝙚𝙖𝙩𝙞𝙣𝙜 𝙨𝙩𝙧𝙖𝙩𝙚𝙜𝙞𝙘 𝙧𝙚𝙨𝙚𝙧𝙫𝙚𝙨 𝙤𝙛 𝙚𝙨𝙨𝙚𝙣𝙩𝙞𝙖𝙡 𝙞𝙩𝙚𝙢𝙨 𝙬𝙞𝙩𝙝 𝙘𝙡𝙚𝙖𝙧 𝙧𝙤𝙩𝙖𝙩𝙞𝙤𝙣 𝙥𝙧𝙤𝙩𝙤𝙘𝙤𝙡𝙨 I recently spoke with a procurement director at Memorial Hospital who implemented what they call "resilient efficiency"—maintaining JIT for 80% of supplies while creating strategic reserves for critical items like PPE, emergency medications, and specialized equipment. The results? A 12% reduction in emergency purchases, improved response times during local supply disruptions, and—surprisingly—only a 3% increase in overall inventory costs. What's your organization doing to balance efficiency with resilience? Has your procurement strategy evolved since 2020? Share your thoughts in the comments section to share your insights. CIPS MENA #procurementexecutives PureHealth Rafed UAE #HealthcareProcurement #SupplyChainResilience #JustInTime #ProcurementStrategy #HealthcareLeadership #Procurement

Resilience in Pharmaceutical Supply Chains, part 3: What can realistically be achieved? Just yesterday, news came out that the last Antibiotics manufacturing plant in Switzerland is closing, as it is losing money. And it seems that in the EU, there's only one Antibiotics manufacturing site left (Kundl in Austria). As we have seen, one of the major factors to achieve resilience is to have alternate manufacturing sites. As of today, this is very often not the case, cost efficiency has favored centralizing manufacturing of many finished or intermediate products in one site for the entire world. That's economies of scale as from the textbooks, but of course, in todays more risky world, this network design has to be re-visited. There are, however, not infinite resources to build and operate new plants, and transferring pharmaceutical products is also cost and labor intensive. So, companies will need to prioritize for which products they can build resilience. Governments are interested in securing supply of pharmaceuticals, and they need to deploy a mix of incentive and coercive measures. That can go as far as investing in a national manufacturing industry, as is happening eg in Saudi Arabia. I do expect that the mix of non-tariff measures (pricing and regulatory benefits etc) that amount to national manufacturing incentives, as well as tariff threats, will lead to a regionalization of pharma manufacturing, but not for all products - it must be economically viable. I do also expect that Contract Manufacturing will play a very important role in this, as there is overall no shortage of capacity today, and sharing sites between companies seems often a better use of capital investments - many companies, especially mid sized and small ones, actually could not even afford going on a regional plant building spree. With that said, I don't think that even the Galenical part of many Pharmaceutical Supply Chains will be made fully resilient, realistically there will not be Dual Sourcing everywhere, because it would be too expensive. And the Chemical part, the manufacturing of API, is another thorny topic altogether, I will talk about this in the next video.

My view on TPRM Resilience in Pharmaceutical Sector! 🌐 Strengthening TPRM Resilience in the Pharma Sector The pharmaceutical industry’s lifeline is its complex network of suppliers, contract manufacturers, research partners, logistics providers, and technology vendors. Any disruption—from cyberattacks to supply chain delays—can impact drug availability, compliance, and ultimately, patient safety. Resilient Third-Party Risk Management (TPRM) goes beyond periodic due diligence. It demands: ✅ Continuous monitoring of supplier risks ✅ Real-time compliance tracking (FDA, EMA, GMP) ✅ Robust contingency and incident response plans ✅ Collaborative risk mitigation with partners Leveraging AI, analytics, and digital platforms can help identify emerging threats, ensure quality standards, and protect sensitive data. The goal? A supply chain that remains secure, compliant, and agile—even in global crises. In pharma, resilience isn’t optional—it’s lifesaving. Embedding TPRM resilience ensures that critical medicines reach patients without interruption, safeguarding both health outcomes and public trust. #Pharma #TPRM #SupplyChainResilience #RiskManagement #PatientSafety #Compliance #EY #Lifescience #RegulatoryCompliance Ramakrishnan Krishnan Karthik Balaji Rangarajan Ankur Mehta Rohit M. Rishabh Jain Reema Raheja Shantanu RoyKanjilal Vineeth Gopal

Last week’s executive order directing HHS ASPR to identify and stockpile active pharmaceutical ingredients (#APIs) for critical medicines marks another step in reshaping the US pharma #supplychain. With only ~10% (by volume) of APIs currently produced domestically, the initiative aims to build a strategic reserve and prioritize domestic sourcing where possible. Government-backed stockpiling adds another dimension to the investment story we’ve been tracking in recent months. Companies like Eli Lilly and Company, with its $27 billion commitment to four plants, three API-focused facilities, and AbbVie, with its forthcoming North Chicago plant, have already signaled the scale of private sector momentum behind reshoring. The addition of the federal API reserve (SAPIR) could accelerate them by de-risking upfront capital outlays and shortening the path to ROI. Taken together, these moves reinforce the broader trend and gradual alignment of public policy levers with private sector strategy to reshape US #pharmamanufacturing. At its core, the discussion ultimately comes back to patients. APIs are the foundation of our medicines, and one of the central questions is whether a more stable domestic supply could help reduce the risk of shortages that disrupt treatment. Strategic reserves could play an important role in safeguarding continuity of care if global supply chains come under stress. As industry leaders and policymakers continue to navigate this reshoring effort, the question will be whether these stockpiling initiatives can help build a more resilient, patient-focused ecosystem that balances economic viability with uninterrupted access to essential medicines.